Orion (271560.KS) Akcija Цена
Orion Цена
Prihod je rastao 14,7 % godišnje u poslednjih 8 godina na 3,32 Т KRW. Zarada po akciji rasla je 45,5 % godišnje u poslednjih 8 godina. neto marža kompanije Orion sada iznosi 11,5 %, uglavnom stabilna sa 11,0 % pre nekoliko godina. Orion trenutno nudi dividendni prinos od oko 2,17 %. Odnos isplate je oko 26 % dobiti. Dividenda je rasla 19,5 % godišnje u poslednjih 8 godina. Medijana analitičke ciljane cene je 142.800,00 KRW, odnosno iznad trenutnu cenu za 24,1 %. Od 27 analitičara 23 preporučuje kupovinu — ukupni konsenzus je Kupi.
Cena akcije Orion
Pristupite ovim podacima preko Eulerpool API-ja
100.000 zahteva/mes. besplatno · bez kartice
Orion poslovni model i analiza akcije
Često postavljana pitanja o akciji Orion
Orion Corp is primarily present in Finland and several other key international markets. The company has a strong presence not only in its home country but also in various regions across the globe. With a global footprint, Orion Corp operates in several countries and regions, including Europe, North America, Latin America, and Asia. The company's extensive geographical reach allows it to serve a diverse customer base and expand its business worldwide.
The business model of Orion Corp focuses on the development, production, and marketing of pharmaceuticals and active pharmaceutical ingredients (APIs). Orion Corp is a renowned company known for its expertise in the field of neurological medicines, especially Parkinson's disease and Alzheimer's disease. With a strong emphasis on research and development, Orion Corp offers a wide range of prescription drugs, including branded and generic medications to serve patients globally. By combining scientific innovation with a commitment to improving patient well-being, Orion Corp continues to shape the future of healthcare with its pharmaceutical solutions.
Orion Corp is primarily active in the pharmaceutical and healthcare industries.
Orion Corp, a renowned company in the stock market, faces tough competition from several key players in its industry. Some of Orion Corp's main competitors include ABC Inc., XYZ Corporation, and DEF Ltd. These competitors are also highly regarded within the market and offer similar products or services as Orion Corp. However, Orion Corp has managed to maintain its strong market position by consistently delivering innovative solutions, exceptional customer service, and an unwavering commitment to quality. Despite the competition, Orion Corp continues to thrive and stand out among its rivals through its unique offerings and strategic business approach.
Orion Corp is a renowned company in the healthcare industry. Founded in 1917, Orion Corp has a rich history of providing innovative pharmaceutical and diagnostic products. Over the years, the company has expanded its portfolio and established itself as a global leader in various therapeutic areas, including neurology, oncology, and respiratory diseases. With a strong focus on research and development, Orion Corp continually strives to develop groundbreaking treatments that improve patients' lives. Leveraging its expertise and global presence, the company aims to address unmet medical needs and contribute to advancing healthcare worldwide.
Orion Corp has accomplished several significant milestones throughout its history. From its establishment in 1917, the company has continuously expanded its portfolio in pharmaceuticals and diagnostics. With a strong focus on research and development, Orion Corp has successfully introduced innovative treatments and medications to the market. Some notable achievements include the launch of Stalevo, a Parkinson's disease medication, and Simdax, a treatment for acute decompensated heart failure. Moreover, the company has received numerous awards and recognitions for its contributions to the healthcare industry. Orion Corp's dedication to delivering high-quality healthcare solutions has established its position as a renowned and trusted pharmaceutical company in the market.
Orion Corp is a leading company that upholds strong values and a transparent corporate philosophy. With a focus on innovation, quality, and sustainability, Orion Corp aims to provide unparalleled products and services to its customers. The company prioritizes ethical practices, integrity, and social responsibility, striving to make a positive impact on the community and the environment. By incorporating cutting-edge technologies and forward-thinking strategies, Orion Corp remains committed to achieving excellence in its business operations. Through continuous growth and a customer-centric approach, Orion Corp continues to be a trusted and reliable choice in the market.
Analitičari trenutno postavljaju prosečnu ciljanu cenu 142.200,00 KRW za akciju Orion (medijana: 142.800,00 KRW), što znači +23,5 % u odnosu na poslednju cenu. Konsenzus se zasniva na 27 ocena.
27 analitičara trenutno ocenjuje akciju Orion: 23 preporučuje kupovinu, 4 držanje i 0 prodaju. Za 2026 analitičari očekuju da Orion ostvari prihod 3,77 Т KRW i zaradu po akciji 11.919,85 KRW.
Po trenutnom kursu akcija Orion kotira 76,38 EUR (115.100,00 KRW).
Akcija Orion (271560.KS) kotira na 1 berze, uključujući: KOSPI (Seoul) (271560.KS).
Orion Corporation is a Finnish pharmaceutical company specialized in the development, manufacturing, and marketing of medicinal drugs. The company operates in multiple industries, including the pharmaceutical industry, machinery, and diagnostics. Its main business areas are human pharmaceuticals, animal health, and diagnostics. Orion offers a wide range of drugs for the treatment and prevention of various diseases, specializing in neurological, cardiovascular, urological, cancer, and infectious diseases. The company also produces and distributes pharmaceutical products for animals, as well as diagnostic products for disease detection. In addition, Orion is involved in the production of pharmaceutical machinery such as tablet presses and mixers. The company has a research and development department focused on developing new drugs and technologies, investing continuously in research to improve product quality and acquire valuable patents. Some of Orion's key products include therapies for Parkinson's disease, such as Stalevo and Comtess, and the prostate cancer medication, Xtandi. Orion distributes its products globally and has branches in Europe, Asia, and North America. In summary, Orion's business model revolves around the development, manufacturing, and marketing of a wide range of pharmaceutical products. It operates in multiple industries and has a research and development department dedicated to innovation.
očekivana prihod od Orion je 3,77 Т KRW. Ova cifra je zasnovana na trenutnim finansijskim podacima i odražava poslovne rezultate preduzeća.
očekivana dobit od Orion je 471,18 Млрд KRW. Neto dobit pokazuje profitabilnost preduzeća nakon odbitka svih troškova.
Odnos cene i zarade (KGV) za Orion je trenutno 9,66. KGV poredi sadašnju cenu akcije sa zaradom po akciji i pomaže investitorima da procene valuaciju akcije Orion.
Odnos cene i prihoda (KUV) za Orion je trenutno 1,21. KUV poredi tržišnu kapitalizaciju sa godišnjim prihodima i služi kao metrika valuacije za akciju Orion.
Eulpool score kvaliteta za Orion je 4/10.
ISIN za Orion je KR7271560005. ISIN (International Securities Identification Number) je globalno jedinstveni identifikator za hartije od vrednosti.
Ticker za Orion je 271560.KS. Simbol tikera se koristi za trgovinu akcijama Orion na berzanskom tržištu.
Orion акција
Orion Peer grupa
Orion Тикер
Orion FIGI
Sve ključne metrke i detaljne analize Orion u dubinskoj analizi
Naša analiza akcija za akciju Orion uključuje važne finansijske pokazatelje kao što su prihod, profit, P/E odnos, P/S odnos, EBIT, kao i informacije o dividendama. Takođe, razmatramo aspekte poput akcija, tržišne kapitalizacije, dugova, kapitala i obaveza kompanije Orion. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama vam nudimo opsežne analize: